Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 juil. 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 juin 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2022, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference
02 juin 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the 2022 Jefferies Healthcare Conference on Thursday,...
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
17 mai 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal...
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
16 mai 2022 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 mai 2022 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2022, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics Reports First Quarter 2022 Financial Results
05 mai 2022 16h01 HE
|
Travere Therapeutics, Inc.
Submitted New Drug Application (NDA) for sparsentan in IgA nephropathy in March 2022 Results from Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU) presented at the Society...
Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
03 mai 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the BofA...
Travere Therapeutics to Report First Quarter 2022 Financial Results
28 avr. 2022 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close...
Travere Therapeutics Announces Plan for Chief Financial Officer Transition
20 avr. 2022 16h30 HE
|
Travere Therapeutics, Inc.
Laura Clague to step-down as CFO in August 2022 and retire in 2023 Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in...